The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 8, 2013, Pages 664-672

  Bi, Y ^a   Tong, G Y ^a   Yang, H J ^a   Cai, M Y ^b   Ma, J H ^c   Liang, J ^d   Xin, B ^e   Miao, H ^f   Peng, Z H ^g   Zhu, D L ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d XUZHOU CENTRAL HOSPITAL   (China)

^e Nanjing Governmental Hospital   (China)

^f THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Beta cell function; Glucagon; Glucagon like peptide 1; Metformin; Non obese; Type 2 diabetes mellitus

Indexed keywords

GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; CHINESE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FORMULATION; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BETA CELL FUNCTION; GLUCAGON; GLUCAGON-LIKE PEPTIDE-1; METFORMIN; NON-OBESE; TYPE 2 DIABETES MELLITUS;

ADULT; AGED; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84887793582     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2443     Document Type: Article

References (36)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
2. Robertson RP, Harmon J, Tran PO, Poitout V. β-Cell glucotoxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53(Suppl. 1): S119-S124.
3. Prentki M, Nolan CJ. Islet β-cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812.
4. Li YB, Xu W, Liao ZH, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 2004; 27: 2597-2602.
5. Weng JP, Li YB, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008; 371: 1753-1760.
6. Kahn SE, Lachin JM, Zinman B, et al. The ADOPT study group. Effects of rosiglitazone, glyburide, and metformin on b-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-1560.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
8. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006; 29: 2361-2364.
9. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
10. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167.
11. Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One 2013; 8: e57222.
12. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS 13): relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed three years. BMJ 1995; 310: 83-88.
13. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55: S2-S5.
14. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
15. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51: S134-S137.
16. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-5541.
17. Chan JC, Deerochanawong C, Shera AS, et al. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective. Diabetes Res Clin Pract 2007; 75: 255-266.
18. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991; 34: 483-487.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
20. Steering Committee of the Western Pacific Region of the World Health Organization, the International Association for the Study of Obesity, and the International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia Pty Ltd, Melbourne, Australia, 2000.
21. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994; 17: 152-154.
22. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-Cell function preservation after 3.5years of intensive diabetes therapy. Diabetes Care 2012; 35: 1406-1412.
23. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
24. Defronzo RA, Banerji MA, Bray GA, et al. For the ACT NOW study group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010; 53: 435-445.
25. Bi Y, Zeng LY, Zhu DL, et al. Association of β-cell function and insulin sensitivity with fasting and 2h plasma glucose in a large Chinese population. Diabetes Obes Metab 2012; 14: 174-180.
26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
27. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2004; 17: 336-342.
28. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and Ghrelin in obese patients with type2 diabetes mellitus. Diabet Med 2012; 29: e205-e210.
29. Hinke SA, Kühn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
30. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219-222.
31. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011; 54: 339-349.
32. Reimann F, Gribble FM. Glucose-sensing in glucagon-like eptide-1-secreting cells. Diabetes 2002; 51: 2757-2763.
33. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122: 4-12.
34. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-260.
35. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
36. Bei-Fan Z. Cooperative meta-analysis group of working group on obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Asia Pac J Clin Nutr 2002; 11: S685-S693.